Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE DATED JANUARY 31, 2017 - TENAX THERAPEUTICS, INC. | tenx_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): January 31,
2017
Tenax Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-34600
|
|
26-2593535
|
(State
or other jurisdiction of incorporation)
|
|
(CommissionFile
Number)
|
|
(IRS
EmployerIdentification No.)
|
ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address
of principal executive offices) (Zip Code)
919-855-2100
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
8.01
Other Events.
On
January 31, 2017, Tenax Therapeutics, Inc. issued a press release
announcing top-line results from its Phase 3 LEVO-CTS trial. A copy
of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference
Item
9.01
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
|
Description
|
Press
Release dated January 31, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Tenax Therapeutics, Inc.
|
|
|
|
|
|
|
Date:
January 31, 2017
|
By:
|
/s/
John
Kelley
|
|
|
|
John
Kelley
|
|
|
|
Chief
Executive Officer
|
|
Exhibit Index
Exhibit No.
|
Description
|
Press
Release dated January 31, 2017
|